Growth factor signaling in metastasis: current understanding and future opportunities (Q38019410)

27 August 2017

Growth factor signaling in metastasis: current understanding and future opportunities (English)

1 reference

27 August 2017

Frank J Lowery

1

1 reference

27 August 2017

Dihua Yu

series ordinal

2

1 reference

27 August 2017

language of work or name

1 reference

1 December 2012

1 reference

Cancer and Metastasis Reviews

27 August 2017

1 reference

27 August 2017

31

1 reference

27 August 2017

3-4

1 reference

27 August 2017

479-491

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-012-9380-x

27 August 2017

0 references

cites work

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Tumor immune escape mechanisms that operate during metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

ErbB receptors: new insights on mechanisms and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Epidermal growth factor receptors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Genes that mediate breast cancer metastasis to lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Genes that mediate breast cancer metastasis to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Identification of heregulin, a specific activator of p185erbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Transfected neu oncogene induces human prostate cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Tyrosine kinase receptor indistinguishable from the c-met protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

The Met tyrosine kinase receptor in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

A point mutation in the MET oncogene abrogates metastasis without affecting transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

TGF-beta signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

The dynamic roles of TGF-β in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

TGF-beta promotes the establishment of renal cell carcinoma bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

TGF-β1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

TGF-β inhibits metastasis in late stage human squamous cell carcinoma of the skin by a mechanism that does not involve Id1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Invasion and metastasis of a mammary tumor involves TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

The loss of TGF-beta signaling promotes prostate cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Angiogenic acceleration of Neu induced mammary tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

A compact VEGF signature associated with distant metastases and poor outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Real-time imaging reveals the single steps of brain metastasis formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

The bone remodeling environment is a factor in breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

RANKL inhibition in the treatment of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Signaling networks assembled by oncogenic EGFR and c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

microRNAs: tiny regulators with great potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

MicroRNAs: genomics, biogenesis, mechanism, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

MIR-99a and MIR-99b modulate TGF-β induced epithelial to mesenchymal plasticity in normal murine mammary gland cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

Neu receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9380-X

10.1007/S10555-012-9380-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference